Vertex Pharmaceuticals Aktie 983327 / US92532F1003
491.78
USD
27.14
USD
5.84 %
13.02.2026
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Vertex Pharmaceuticals Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2025 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2024 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2023 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2022 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2021 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2020 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2019 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2018 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2017 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2016 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Vertex Pharmaceuticals
| 15.3 25 | -2.1 24 | 13.9 23 | 12.8 22 | 9.0 21 | 10.3 20 | 4.5 19 |
Umsatz je Aktie- Vertex Pharmaceuticals
| 46.8 25 | 42.6 24 | 37.8 23 | 33.8 22 | 29.3 21 | 23.6 20 | 15.8 19 |
KGV- Vertex Pharmaceuticals
| 29.6 25 | 29.3 23 | 22.5 22 | 24.4 21 | 23.0 20 | 48.5 19 |
Vertex Pharmaceuticals Inc.: Die Aktie (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
| Gewinn je Aktie (unverwässert) | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 |
| Gewinn je Aktie (verwässert) | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
| Dividende je Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Veränderung Dividende je Aktie in % | - | - | - | - | - | - | - |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Vertex Pharmaceuticals Inc.: Unternehmenskennzahlen (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 46.80 | 42.59 | 37.77 | 33.76 | 29.26 | 23.57 | 15.84 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 29.59 | - | 29.28 | 22.52 | 24.37 | 22.96 | 48.50 |
| KGV (Jahresendkurs, Gewinn verwässert) | 29.59 | - | 29.28 | 22.52 | 24.37 | 22.96 | 48.50 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 71.40 | 71.07 | 76.15 | 76.65 | 75.19 | 73.92 | 73.15 |
| Fremdkapitalquote in % | 28.60 | 28.93 | 23.85 | 23.35 | 24.81 | 26.08 | 26.85 |
Vertex Pharmaceuticals Inc.: GuV (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 12’074.60 | 10’984.40 | 9’839.00 | 8’748.20 | 7’604.40 | 6’209.40 | 4’130.28 |
| Umsatzveränderung in % | 9.92 | 11.64 | 12.47 | 15.04 | 22.47 | 50.34 | 35.47 |
| Bruttoergebnis vom Umsatz | 10’267.50 | 9’453.90 | 8’576.80 | 7’667.90 | 6’700.20 | 5’473.10 | 3’582.52 |
| Bruttoergebnisveränderung in % | 8.61 | 10.23 | 11.85 | 14.44 | 22.42 | 52.77 | 35.74 |
| Operatives Ergebnis | 4’760.70 | 4’359.30 | 4’277.30 | 4’182.90 | 2’809.00 | 2’873.10 | 1’169.48 |
| Veränderung Operatives Ergebnis in % | 9.21 | 1.92 | 2.26 | 48.91 | -2.23 | 145.67 | 75.80 |
| Ergebnis vor Steuern | 4’643.20 | 248.50 | 4’379.80 | 4’232.40 | 2’730.40 | 3’116.80 | 1’394.92 |
| Veränderung Ergebnis vor Steuern in % | 1’768.49 | -94.33 | 3.48 | 55.01 | -12.40 | 123.44 | 132.39 |
| Ergebnis nach Steuer | 3’953.20 | -535.60 | 3’619.60 | 3’322.00 | 2’342.10 | 2’711.65 | 1’176.81 |
| Veränderung Ergebnis nach Steuer in % | - | - | 8.96 | 41.84 | -13.63 | 130.42 | -43.87 |
Vertex Pharmaceuticals Inc.: Bilanz (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 7’477 | 6’681 | 5’506 | 4’238 | 3’333 | 3’065 | 2’233 |
| Langzeit Gesamtverbindlichk. je Aktie | 14.24 | 12.13 | 7.60 | 5.82 | 4.68 | 4.57 | 3.47 |
| Eigenkapital | 18’666 | 16’410 | 17’580 | 13’913 | 10’100 | 8’687 | 6’085 |
| Veränderung Eigenkapital in % | 13.75 | -6.66 | 26.36 | 37.75 | 16.27 | 42.75 | 37.20 |
| Bilanzsumme | 26’143 | 23’091 | 23’086 | 18’151 | 13’433 | 11’752 | 8’318 |
| Veränderung Bilanzsumme in % | 13.22 | 0.02 | 27.19 | 35.13 | 14.30 | 41.27 | 33.18 |
Vertex Pharmaceuticals Inc.: Sonstige Angaben (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 |
| Veränderung Gewinn je Aktie (unverwässert) in % | - | -114.79 | 8.28 | 42.72 | -12.91 | 127.66 | -44.37 |
| Gewinn je Aktie (verwässert) | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
| Veränderung Gewinn je Aktie (verwässert) in % | - | -114.95 | 8.37 | 42.28 | -12.47 | 128.04 | -44.20 |
| Anzahl Mitarbeiter | 6’400 | 6’100 | 5’400 | 4’800 | 3’900 | 3’400 | 3’000 |
| Veränderung Anzahl Mitarbeiter in % | 4.92 | 12.96 | 12.50 | 23.08 | 14.71 | 13.33 | 20.00 |
Vertex Pharmaceuticals Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 06.05.2026 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 30.07.2026 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 09.11.2026 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 09.02.2027 |
Vertex Pharmaceuticals Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q4 2025 Earnings Release | 12.02.2026 |
| Quartalszahlen | Q3 2025 Earnings Release | 03.11.2025 |
| Quartalszahlen | Q2 2025 Earnings Release | 04.08.2025 |
| Hauptversammlung | Annual General Meeting | 14.05.2025 |
| Quartalszahlen | Q1 2025 Earnings Release | 05.05.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 10.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 04.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 01.08.2024 |
| Hauptversammlung | Annual General Meeting | 15.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 06.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 05.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 06.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 01.08.2023 |
| Hauptversammlung | Annual General Meeting | 17.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 01.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 07.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 18.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 26.01.2022 |
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 3’000 | 3’400 | 3’900 | 4’800 | 5’400 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1.38 | 1.83 | 1.95 | 1.82 | 1.82 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4’823 | 8’133 | 9’561 | 13’235 | 14’144 |
| Summe Anlagevermögen | 3’496 | 3’618 | 3’872 | 4’916 | 8’942 |
| Summe Aktiva | 8’318 | 11’752 | 13’433 | 18’151 | 23’086 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 2’233 | 3’065 | 3’333 | 4’238 | 5’506 |
| Summe Eigenkapital | 6’085 | 8’687 | 10’100 | 13’913 | 17’580 |
| Summe Passiva | 8’318 | 11’752 | 13’433 | 18’151 | 23’086 |
Adresse
| 50 Northern Avenue, 02210 Boston | |
| Telefon | +1 (617) 341-6100 |
| URL | http://www.vrtx.com |
Management
|
Agam Upadhyay
Senior VP, Chief Digital & Information Officer |
|
Alan M. Garber
Independent Director |
|
Amit K. Sachdev
Chief Patient & External Affairs Officer |
|
Bruce I. Sachs
Lead Independent Director |
|
Carmen Bozic
Chief Medical Officer & EVP-Medical Affairs |
|
Catherine Rutten
Vice President-International & Government Affairs |
|
Charles F. Wagner
EVP, Chief Financial & Operating Officer |
|
Diana L. McKenzie
Independent Director |
|
Duncan J. McKechnie
Chief Commercial Officer |
|
Edward Morrow Atkinson
Chief Technical Operations Officer & Executive VP |
|
Jeffrey M. Leiden
Executive Chairman |
|
Jennifer Schneider
Independent Director |
|
Jonathan Prim Biller
Chief Legal Officer & Executive Vice President |
|
Joy Liu
Secretary, Senior Vice President & General Counsel |
|
Kristen C. Ambrose
Chief Accounting Officer & Senior Vice President |
|
Lloyd A. Carney
Independent Director |
|
Ludovic Fenaux
Senior VP-International Commercial Operations |
|
Mark Bunnage
Chief Scientific Officer & SVP-Global Research |
|
Michel Lagarde
Independent Director |
|
Nancy A. Thornberry
Independent Director |
|
Nia Tatsis
Chief Regulatory & Quality Officer, Director, EVP |
|
Nicole A. Gabreski
Associate Director-External Innovation |
|
Paul A. Negulescu
Senior Vice President |
|
Reshma Kewalramani
President, Chief Executive Officer & Director |
|
Sangeeta N. Bhatia
Independent Director |
|
Sean Daughtry
Senior Director-Analytical Sciences & Technology |
|
Stephanie Franklin
Chief Human Resources Officer & Senior VP |
|
Suketu P. Upadhyay
Independent Director |
|
Susie Lisa
Senior Vice President-Investor Relations |